Seeking Alpha · Jan 13, 2024
Stocks To Watch: Energy Market Drama And Financial Earnings Headline Holiday Week
Stay informed of upcoming market events with Seeking Alpha's Stocks to Watch.
RY
NASDAQ · RYZB
RayzeBio, Inc. Common Stock
Healthcare · Biotechnology
$62.49
Up+$0.01 (+0.02%)
Updated Sep 13, 2026, 3:27 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 3.75B
- P/E ratio
- -35.73
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 282.72K
- Avg. volume
- 762.04K
Price performance
RYZB price history
1M range · 0 trading sessions · Daily adjusted prices
RYZB does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest RYZB news
The latest Smart Investors Daily articles mentioning RYZB.
Stock researchCompany · Overview
RYZB research
Overview
Company profile and research snapshot.
Company profile
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.
Analyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 26, 2023 | William Blair | Market Perform | — |
| Oct 11, 2023 | Evercore ISI Group | Outperform | — |
| Oct 10, 2023 | Jefferies | Buy | — |
| Oct 10, 2023 | Truist Securities | Buy | — |
| Oct 10, 2023 | JP Morgan | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Jan 5, 2024
Cramer Says This 'Inexpensive' Stock Is 'Doing Some Great Things With Aerospace'
Jim Cramer said WK Kellogg Co (NYSE: KLG) doesn’t have a "lot of growth, and it doesn’t have a lot of yield." He prefers Kellanova (NYSE: K) to that one. Recall how, in September, Kellogg split into two independently traded companies. The global snacking business was formed into Kellanova and the North American cereal brand became WK Kellogg. When asked about Lithia Motors, Inc. (NYSE: LAD), Cramer said, "I like CarMax, Inc. (NYSE: KMX), they're magnificent, and then I like Lithia." The "Mad Money" host also said he doesn’t recommend the tobacco companies, when asked about Altria Group, Inc. (NYSE: ...
Benzinga · Dec 27, 2023
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole remaining clinical-stage player with a robust supply chain. In September, Oppenheimer initiated coverage on Fusion Pharmaceuticals, citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies. Most recently, Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of
MarketWatch · Dec 27, 2023
Fusion Pharma climbs as radiopharmaceutical company flagged as potential merger target
Targeted-oncology specialist draws upgrade at Raymond James after big premium paid is for Rayze Bio.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
